NCT07288515

Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus

Observational Prospective Study of Acalabrutinib in Chronic Lymphocytic Leukemia Therapy in Real Clinical Practice in Belarus.

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL

Detailed description

This observational, prospective, multi-center study aims to gather real-world data (RWD) on acalabrutinib's use in routine clinical practice for CLL treatment in Belarus. Patients will be monitored without intervention, and all treatment decisions will be at the clinician's discretion. The study duration per patient will be approximately two years, with periodic data collection at regular intervals, ensuring comprehensive assessment of treatment effectiveness, patient safety, and quality of life metrics.

Conditions

• Chronic Lymphocytic Leukemia

Timeline

• Start date: 2025-12-31
• Primary completion: 2029-12-31
• Completion: 2029-12-31
• First posted: 2025-12-17
• Last updated: 2026-04-17

Locations

1 site across 1 country: Belarus